BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Kissing is an ‘evolutionary conundrum.’ Scientists just mapped its unexpected origins- Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- 10 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- Closets for Your Room: Plan and Utility Features
- Major Scottish gangland figure Steven Lyons arrested in Bali
- Coffee Prices Finish Higher on Brazil Cop Concerns
- Ukraine to get up to 100 French-made Rafale fighter jets
- America's Confided in Cooler in 2024
- Bolsonaro briefly leaves Brazilian prison for medical tests after a fall from his bed
